PCSK9 Inhibitors Market Size, Share & Trends Analysis Report By Product Type (Repatha (Evolocumab), Praluent (Alirocumab), Bococizumab, Others), By Application (Clinical Application, Drug Development, Other), By Region, And By Segment Forecasts, 2025-2034

Report Id: 1298 Pages: 185 Last Updated: 23 May 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Global PCSK9 Inhibitors Market is expected to grow at a 15.0% CAGR during the forecast period for 2025-2034.

Key Industry Insights & Findings from the Report:

  • There is a higher demand for novel treatments that can efficiently control chronic illnesses like high cholesterol.
  • Healthcare practitioners are increasingly acknowledging the advantages of PCSK9 inhibitors in controlling elevated cholesterol levels, especially in patients who are at a high risk of cardiovascular diseases or have familial hypercholesterolemia.
  • In 2023, North America had a significant market dominance and contributed to a substantial portion of the worldwide revenue.
  • These treatments are significantly pricier than conventional cholesterol-lowering meds like statins. Access to healthcare services may be restricted for patients, especially those who lack sufficient insurance coverage or financial means due to affordability concerns.

 PCSK9 Inhibitors Market

Low-density lipoprotein (LDL) receptor degradation is controlled by the proprotein convertase subtilisin/Kexin type 9 serine protease (PCSK9), which reduces the clearance of circulating LDL particles.  PCSK9 inhibitors have been developed as a consequence of controlling PSCK9 levels.  LDL clearance from the blood is inhibited by PCSK9's attachment to low-density lipoprotein receptors (LDLRs), which causes blood levels of LDL to increase. The PCSK9 enzyme is now inhibited with the use of a PCSK9 inhibitor, which increases the number of LDL receptors that can remove LDL from circulation.

Due to a number of factors, comprising an increase in global healthcare spending, a rise in statin resistance among patients with familial hypercholesterolemia, an increase in the risk of cardiovascular diseases like myocardial infarction and coronary revascularization, etc., the PCSK9 Inhibitors market dynamics are anticipated to change in the upcoming years.  The market for PCSK9 Inhibitors will grow significantly if PCSK9 inhibition is used as a preventative approach to reduce the burden of CVD.  The market for PCSK9 inhibitors is also expected to expand due to the effects of these drugs in new therapeutic fields.

Despite the fact that monoclonal antibodies have shown to be the most therapeutically effective PCSK9 inhibitors, additional novel medications are now undergoing various phases of research and will soon be on the market for PCSK9 inhibitors.

Competitive Landscape

Some Major Key Players In The PCSK9 Inhibitors Market:

  • Regeneron Pharmaceuticals, Inc. (Sanofi)
  • Amgen Inc.
  • Novartis AG
  • Innovent
  • CiVi Biopharma
  • LIB Therapeutics, LLC
  • Akeso Pharmaceuticals Inc.
  • Shanghai Junshi Biosciences Co., Ltd
  • Merck & Co., Inc.
  • AstraZeneca
  • Alnylam
  • Affiris
  • BMS
  • Ionis Pharmaceuticals
  • Cyon Therapeutics
  • Daiichi Sankyo
  • Other Market Players

Market Segmentation:

The PCSK9 Inhibitors Market is segmented based on Drug, Modality, Indication and Sales Channel. The Drug Segment comprises Alirocumab, Evolocumab, Inclisiran, Pipeline Drugs (Ebronucimab, Tafolecimab, Lerodalcibep, Others (MK-0616, etc))). The Modality segment includes Fully-humanized monoclonal antibodies, siRNA. The Indication segment categorises into Primary Hyperlipidemia, Familial Hyper Cholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD), and Prevention of Other Cardiovascular Events. By Sales Channel, the market is segmented into Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies.

The North America PCSK9 Inhibitors Market Holds Significant Revenue Share In The Region.

North America is likely to account for a substantial portion of the global PCSK9 inhibitors market during the forecast period because of the presence of well-established enterprises producing and marketing PCSK9 inhibitors. According to the US Department of Health and Human Services, around 805,000 Americans have a heart attack each year. This highlights the importance of medications like PCSK9 inhibitors in lowering cholesterol and preventing heart disease at an early stage. The region's high prevalence of cardiovascular illnesses, combined with new product releases, will drive PCSK9 inhibitor growth in the region. Furthermore, expanding R&D activities and increased awareness and prevalence of risk factors such as diabetes in the general population are expected to drive the North American market during the forecast period.

Recent Developments:

  • In August 2023, Merck initiated two Phase 3 clinical trials for the drug. Previously, Amgen, Regeneron, and Novartis marketed injectable PCSK9 inhibitors. Merck conducted three Phase 3 trials to evaluate the efficacy of MK-0616 in reducing cardiac risk and LDL cholesterol levels among patients with high cholesterol.

The PCSK9 Inhibitors Market Report Scope

Report Attribute Specifications
Growth Rate CAGR CAGR of 15.0% from 2025 to 2034
Quantitative Units Representation of revenue in US$ Mn, and CAGR from 2025 to 2034
Historic Year 2021 to 2024
Forecast Year 2025-2034
Report Coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered By Drug, Modality, Indication and Sales Channel
Regional Scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia
Competitive Landscape Amgen, Eli Lilly, Sanofi, Pfizer, Novartis, Roche, Merck, Alnylam, AstraZeneca, Affiris, BMS, Ionis Pharmaceuticals, Cyon Therapeutics, and Daiichi Sankyo
Customization Scope Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.
Pricing And Available Payment Methods Explore pricing alternatives that are customized to your particular study requirements.

Segmentation of PCSK9 Inhibitors Market-

PCSK9 Inhibitors Market By Drug

  • Alirocumab
  • Evolocumab
  • Inclisiran
  • Pipeline Drugs
    • Ebronucimab
    • Tafolecimab
    • Lerodalcibep
    • Others (MK-0616, etc)

pcsk9 inhibitor

PCSK9 Inhibitors MarketBy Modality

  • Fully-humanized monoclonal antibodies
  • siRNA

PCSK9 Inhibitors MarketBy Indication

  • Primary Hyperlipidemia
  • Familial Hyper Cholesterolemia
  • Atherosclerotic Cardiovascular Disease (ASCVD)
  • Prevention of Other Cardiovascular Events

PCSK9 Inhibitors MarketBy Sales Channel

  • Hospitals
  • Specialty Clinics
  • Retail Pharmacies
  • Online Pharmacies

PCSK9 Inhibitors Market By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Chapter 1.          Methodology and Scope

1.1.        Research Methodology

1.2.        Research Scope & Assumptions

Chapter 2.          Executive Summary

Chapter 3.          Global PCSK9 Inhibitor Market Snapshot

Chapter 4.          Global PCSK9 Inhibitor Market Variables, Trends & Scope

4.1.        Market Segmentation & Scope

4.2.        Drivers

4.3.        Challenges

4.4.        Trends

4.5.        Investment and Funding Analysis

4.6.        Porter's Five Forces Analysis

4.7.        Incremental Opportunity Analysis (US$ MN), 2021-2034

4.8.        Global PCSK9 Inhibitor Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034

4.9.        Competitive Landscape & Market Share Analysis, By Key Player (2021)

4.10.     Use/impact of AI on PCSK9 Inhibitor Market Industry Trends

Chapter 5.          PCSK9 Inhibitor Market Segmentation 1: By Drug, Estimates & Trend Analysis

5.1.        Market Share by Drug, 2024 & 2034

5.2.        Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug:

5.2.1.    Alirocumab

5.2.2.    Evolocumab

5.2.3.    Inclisiran

5.2.4.    Pipeline Drugs

5.2.4.1. Ebronucimab

5.2.4.2. Tafolecimab

5.2.4.3. Lerodalcibep

5.2.4.4. MK-0616

Chapter 6.          PCSK9 Inhibitor Market Segmentation 2: By Modality, Estimates & Trend Analysis

6.1.        Market Share by Modality, 2024 & 2034

6.2.        Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Modality:

6.2.1.    Fully-humanized Monoclonal Antibodies

6.2.2.    siRNA

Chapter 7.          PCSK9 Inhibitor Market Segmentation 3: By Indication, Estimates & Trend Analysis

7.1.        Market Share by Indication, 2024 & 2034

7.2.        Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:

7.2.1.    Primary Hyperlipidemia

7.2.2.    Familial Hyper Cholesterolemia

7.2.3.    Atherosclerotic Cardiovascular Disease (ASCVD)

7.2.4.    Prevention of Other Cardiovascular Events

Chapter 8.          PCSK9 Inhibitor Market Segmentation 4: By Sales Channel, Estimates & Trend Analysis

8.1.        Market Share by Sales Channel, 2024 & 2034

8.2.        Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Sales Channel:

8.2.1.    Hospitals

8.2.2.    Specialty Clinics

8.2.3.    Retail Pharmacies

8.2.4.    Online Pharmacies

Chapter 9.          PCSK9 Inhibitor Market Segmentation 5: Regional Estimates & Trend Analysis

9.1.        Global PCSK9 Inhibitor Market, Regional Snapshot 2024 & 2034

9.2.        North America

9.2.1.    North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.2.1.1. US

9.2.1.2. Canada

9.2.2.    North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034

9.2.3.    North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034

9.2.4.    North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034

9.2.5.    North America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034

9.3.        Europe

9.3.1.    Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.3.2.    Germany

9.3.3.    U.K.

9.3.4.    France

9.3.5.    Italy

9.3.6.    Spain

9.3.7.    Rest of Europe

9.3.8.    Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034

9.3.9.    Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034

9.3.10.  Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034

9.3.11.  Europe PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034

9.4.        Asia Pacific

9.4.1.    Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.4.2.    India

9.4.3.    China

9.4.4.    Japan

9.4.5.    Australia

9.4.6.    South Korea

9.4.7.    Hong Kong

9.4.8.    Southeast Asia

9.4.9.    Rest of Asia Pacific

9.4.10.  Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034

9.4.11.  Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034

9.4.12.  Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034

9.4.13.  Asia Pacific PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034

9.5.        Latin America

9.5.1.    Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.5.2.    Brazil

9.5.3.    Mexico

9.5.4.    Rest of Latin America

9.5.5.    Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034

9.5.6.    Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034

9.5.7.    Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034

9.5.8.    Latin America PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034

9.6.        Middle East & Africa

9.6.1.    Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034

9.6.2.    GCC Countries

9.6.3.    Israel

9.6.4.    South Africa

9.6.5.    Rest of Middle East and Africa

9.6.6.    Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Drug, 2021-2034

9.6.7.    Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Modality, 2021-2034

9.6.8.    Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034

9.6.9.    Middle East & Africa PCSK9 Inhibitor Market Revenue (US$ Million) Estimates and Forecasts by Sales Channel, 2021-2034

Chapter 10.        Competitive Landscape

10.1.     Major Mergers and Acquisitions/Strategic Alliances

10.2.     Company Profiles

10.2.1.  Regeneron Pharmaceuticals, Inc. (Sanofi)

10.2.1.1.             Business Overview

10.2.1.2.             Key Product/Service Overview

10.2.1.3.             Financial Performance

10.2.1.4.             Geographical Presence

10.2.1.5.             Recent Developments with Business Strategy

10.2.2.  Amgen Inc.

10.2.3.  Novartis AG

10.2.4.  Innovent

10.2.5.  CiVi Biopharma

10.2.6.  LIB Therapeutics, LLC

10.2.7.  Akeso Pharmaceuticals Inc.

10.2.8.  Shanghai Junshi Biosciences Co., Ltd

10.2.9.  Merck & Co., Inc.

10.2.10.              AstraZeneca

10.2.11.              Alnylam

10.2.12.              Affiris

10.2.13.              BMS

10.2.14.              Ionis Pharmaceuticals

10.2.15.              Cyon Therapeutics

10.2.16.              Daiichi Sankyo

10.2.17.              Other Market Players         

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
4775
Security Code field cannot be blank!

Frequently Asked Questions

PCSK9 Inhibitors Market is expected to grow at a 15.0% CAGR during the forecast period for 2025-2034

Amgen, Eli Lilly, Sanofi, Pfizer, Novartis, Roche, Merck, Alnylam, AstraZeneca, Affiris, BMS, Ionis Pharmaceuticals, Cyon Therapeutics, and Daiichi Sa

Drug, Modality, Indication and Sales Channel are the key segments of the PCSK9 Inhibitors Market.

North American region is leading the PCSK9 Inhibitors Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying